Methods of treating glioblastoma
AssigneeCelgene Quanticel Research, Inc.
InventorsEllen FILVAROFF, Bishoy HANNA, Manisha LAMBA, Ida ARONCHIK
Life of this patent
Estimating the term…
Abstract
The present application relates generally to methods for treating glioblastoma, or glioblastoma multiforme (GBM), with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, or the pharmaceutically acceptable salt thereof.
Claims45
A method of treating glioblastoma multiforme (GBM) in a newly diagnosed GBM subject in need thereof comprising:
- (i) administering to the newly diagnosed GBM subject, a concomitant treatment of radiotherapy with temozolomide and a compound having the structure of Formula (I),
- or a pharmaceutically acceptable salt thereof;
- thereafter
- (ii) adjunctively administering temozolomide and the compound of Formula (I) or a pharmaceutically acceptable salt thereof without radiotherapy;
- and thereafter
- (iii) administering the compound of Formula (I) or a pharmaceutically acceptable salt thereof as a monotherapy.
A method of treating glioblastoma multiforme (GBM) in a subject in need thereof comprising adjunctively administering temozolomide and the compound of having the structure of Formula (I),
- or a pharmaceutically acceptable salt thereof without radiotherapy, and
- wherein administering the temozolomide and the compound of Formula (I) are in a 28 day cycle.
A method of treating glioblastoma multiforme (GBM) in a subject in need thereof comprising administering a monotherapy treatment of 45 mg of a compound having the structure of Formula (I),
- or a pharmaceutically acceptable salt thereof on Days 1-4 of a 28 day cycle, and
- wherein the compound is administered in an amount sufficient to result in a mean ratio of compound concentration in the resected brain tissue to compound concentration in plasma of from about 0.50 to about 1.50.
The method of claim 22, wherein administering the compound of Formula (I) or a pharmaceutically acceptable salt thereof is over two, three, four, five, six, seven, eight, nine, or ten 28 day cycles.
Dependencies are inferred from the claim text.